Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).

scientific article published on 09 September 2011

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.VACCINE.2011.08.098
P698PubMed publication ID21907749
P5875ResearchGate publication ID51639223

P50authorJosep Maria GatellQ17030537
Agathe LeónQ56865082
Vicens Diaz-BritoQ56867697
José AlcamíQ60617155
Juan García-ArriazaQ79782431
Giuseppe PantaleoQ88061163
José Luis JiménezQ95947031
Beatriz PerdigueroQ112248161
Juan Carlos López Bernaldo de QuirósQ114406508
Judit PichQ114406509
Joan Albert ArnaizQ114406510
Mariano EstebanQ30004051
Mª Ángeles Muñoz-FernándezQ40088018
Felipe GarcíaQ41350341
Carmen E GómezQ42100464
Peter LiljeströmQ55136644
P2093author name stringJonathan Weber
Montserrat Plana
Iñaki Pérez
Amparo Alvarez
Nuria González
Alberto C Guardo
Victoria Jiménez
Matilde Sánchez Conde
María J Maleno
Jose L Nájera
P2860cites workThe Spanish HIV BioBank: a model of cooperative HIV researchQ24288934
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenQ24612082
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in womenQ24629582
Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletionsQ27320923
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialQ28972526
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in ThailandQ29547531
Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccineQ30977303
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateQ33749950
The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxvirusesQ34469355
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjectsQ34593969
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individualsQ35844057
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesQ36446900
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trialQ36618096
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus AnkaraQ36692389
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysisQ37413781
Poxvirus vector-based HIV vaccinesQ37803318
Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag cQ39028785
A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism.Q39643952
MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)Q40901244
Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primatesQ42100401
Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDSQ42575428
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteersQ44590524
Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.Q45235855
Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteersQ45423782
A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humansQ45661091
EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C aloneQ46576663
Smallpox vaccination and its consequences: first experiences with the highly attenuated smallpox vaccine "MVA".Q53850523
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.Q54454033
P433issue46
P407language of work or nameEnglishQ1860
P921main subjectHIV/AIDSQ12199
phase I clinical trialQ5452194
vector-based vaccineQ104783588
P304page(s)8309-8316
P577publication date2011-09-09
P1433published inVaccineQ7907941
P1476titleSafety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)
P478volume29